Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission

Ho Lee Sung, Lool Abebe, Elisabeth M. Paietta, Avi Israel Einzig, Peter H. Wiernik

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite major advances in the treatment of acute myeloid leukemia (AML) in adults over the last 3 decades, most patients with other than acute promyelocytic leukemia (APL) still succumb to the disease. For young adults (<60 years of age), death during initial treatment has become the exception rather than the rule it once was, primarily due to major improvements in supportive care, and approximately 70% will achieve a complete remission (CR) with appropriate treatment. However, even among young adults with non-APL AML, only about 25% are cured with present-day therapy, and most relapse and die well within several years of obtaining a first CR. Relapse is usually assumed to be the result of subclinical disease that persisted throughout initial treatment. However, occasional reports of very late relapses of AML suggest that other mechanisms, such as the development of a secondary leukemia may be operative in at least some patients. We report here an extremely late reappearance of AML and discuss the implications of this observation.

Original languageEnglish (US)
Pages (from-to)455-457
Number of pages3
JournalAmerican Journal of Hematology
Volume84
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Acute Myeloid Leukemia
Recurrence
Young Adult
Therapeutics
Acute Promyelocytic Leukemia
Leukemia

ASJC Scopus subject areas

  • Hematology

Cite this

Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission. / Sung, Ho Lee; Abebe, Lool; Paietta, Elisabeth M.; Einzig, Avi Israel; Wiernik, Peter H.

In: American Journal of Hematology, Vol. 84, No. 7, 07.2009, p. 455-457.

Research output: Contribution to journalArticle

@article{1411264d404f490c83f82d9fef801379,
title = "Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission",
abstract = "Despite major advances in the treatment of acute myeloid leukemia (AML) in adults over the last 3 decades, most patients with other than acute promyelocytic leukemia (APL) still succumb to the disease. For young adults (<60 years of age), death during initial treatment has become the exception rather than the rule it once was, primarily due to major improvements in supportive care, and approximately 70{\%} will achieve a complete remission (CR) with appropriate treatment. However, even among young adults with non-APL AML, only about 25{\%} are cured with present-day therapy, and most relapse and die well within several years of obtaining a first CR. Relapse is usually assumed to be the result of subclinical disease that persisted throughout initial treatment. However, occasional reports of very late relapses of AML suggest that other mechanisms, such as the development of a secondary leukemia may be operative in at least some patients. We report here an extremely late reappearance of AML and discuss the implications of this observation.",
author = "Sung, {Ho Lee} and Lool Abebe and Paietta, {Elisabeth M.} and Einzig, {Avi Israel} and Wiernik, {Peter H.}",
year = "2009",
month = "7",
doi = "10.1002/ajh.21431",
language = "English (US)",
volume = "84",
pages = "455--457",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission

AU - Sung, Ho Lee

AU - Abebe, Lool

AU - Paietta, Elisabeth M.

AU - Einzig, Avi Israel

AU - Wiernik, Peter H.

PY - 2009/7

Y1 - 2009/7

N2 - Despite major advances in the treatment of acute myeloid leukemia (AML) in adults over the last 3 decades, most patients with other than acute promyelocytic leukemia (APL) still succumb to the disease. For young adults (<60 years of age), death during initial treatment has become the exception rather than the rule it once was, primarily due to major improvements in supportive care, and approximately 70% will achieve a complete remission (CR) with appropriate treatment. However, even among young adults with non-APL AML, only about 25% are cured with present-day therapy, and most relapse and die well within several years of obtaining a first CR. Relapse is usually assumed to be the result of subclinical disease that persisted throughout initial treatment. However, occasional reports of very late relapses of AML suggest that other mechanisms, such as the development of a secondary leukemia may be operative in at least some patients. We report here an extremely late reappearance of AML and discuss the implications of this observation.

AB - Despite major advances in the treatment of acute myeloid leukemia (AML) in adults over the last 3 decades, most patients with other than acute promyelocytic leukemia (APL) still succumb to the disease. For young adults (<60 years of age), death during initial treatment has become the exception rather than the rule it once was, primarily due to major improvements in supportive care, and approximately 70% will achieve a complete remission (CR) with appropriate treatment. However, even among young adults with non-APL AML, only about 25% are cured with present-day therapy, and most relapse and die well within several years of obtaining a first CR. Relapse is usually assumed to be the result of subclinical disease that persisted throughout initial treatment. However, occasional reports of very late relapses of AML suggest that other mechanisms, such as the development of a secondary leukemia may be operative in at least some patients. We report here an extremely late reappearance of AML and discuss the implications of this observation.

UR - http://www.scopus.com/inward/record.url?scp=67649678810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649678810&partnerID=8YFLogxK

U2 - 10.1002/ajh.21431

DO - 10.1002/ajh.21431

M3 - Article

VL - 84

SP - 455

EP - 457

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -